We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.

This study has been withdrawn prior to enrollment.
(Enrollment difficulties)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00365027
First Posted: August 16, 2006
Last Update Posted: September 4, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
HaEmek Medical Center, Israel
August 15, 2006
August 16, 2006
September 4, 2015
Not Provided
Not Provided
  • Implantation rate per transfer
  • Pregnancy rate per embryo transfer
  • Implantation rate per IVF cycle
  • Pregnancy rate per IVF cycle
Same as current
Complete list of historical versions of study NCT00365027 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.
Not Provided
It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Ovarian Hyperstimulation Syndrome
  • Infertility Drugs
  • Female
Procedure: Delayed embryo transfer
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
Not Provided

Inclusion Criteria:

  • Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation

Exclusion Criteria:

  • Patient's refusal to participate
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00365027
5040706
Not Provided
Not Provided
Not Provided
Not Provided
HaEmek Medical Center, Israel
Not Provided
Study Chair: Eliezer Shalev HaE'mek medical center
HaEmek Medical Center, Israel
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP